Monitoring of response to radiation therapy for human tumor xenografts using99mTc-HL91 (4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime)

Suzuki, Takayuki; Nakamura, Kayoko; Kawase, Takatsugu; Kubo, Atsushi

doi:10.1007/bf02988451

Cited by 10 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The labeling process is simple with mild reaction conditions (45). After the labeling, separation and purification of free iodine and iodine binding peptides must be conducted, which takes a long time, and because the iodine connected to tyrosine is easy to fall off in the body and 123 I is expensive, the application of iodine-labeled LHRH is rare (46,47). …”

Section: Discussionmentioning

confidence: 99%

99mTc-LHRH in tumor receptor imaging

Hao

Sun

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Detection of gonadotropin-releasing hormone (GnRH) also known as luteinizing hormone-releasing hormone (LHRH) in the relevant tumor tissue and normal tissues and organs in vivo expression was investigated. To examine the method of direct radio labeling of LHRH by 99mTc with relatively high radiochemical purity and stability, screening the best labeling conditions, to establish a simple and reliable method of preparation of 99mTc-LHRH was undertaken. The detection of radioisotope-labeled LHRH distribution in mice, LHRH receptor imaging for the study and treatment of cancer basis were evaluated. i) Immunohistochemical staining test was used in 23 patients with hepatocellular carcinoma (HCC), 20 patients with breast cancer, 10 patients with prostate cancer, 20 patients with lung cancer, 20 patients with endometrial cancer tumor cells and normal tissue LHRH-R De Biaoda levels; ii) pre-tin method use direct labeling of LHRH, marking completion of saline or human serum were added at room temperature, the chromatography was measured at different times, to calculate the rate of labeled product and the radiochemical purity of the label, in vivo observation of its stability, and comparative analysis of selected optimal condition; iii) rat pituitary cell membrane protein, the product of in vitro radio-receptor marker analysis, through the saturation and inhibition experiments, was used to test its receptor binding activity; iv) Ch-T method labeled 125I-LHRH, tail vein injection of normal mice at different times were sacrificed, blood and major organs were determined and calculated per gram organization percentage injected dose rate (%, ID/g). Detected by immunohistochemistry in 23 cases of HCC in the LHRH-positive rate was 82.61%, in the corresponding normal tissues, the positive rate was 15%; 20 cases of breast cancer positive rate of 95%, the corresponding normal tissues, the positive rate was 20%; 10 cases of prostate cancer positive rate of 70%, the corresponding normal tissues, the positive rate of 40%; 20 cases of lung cancer positive rate of 85%, the corresponding normal tissues, the positive rate of 15.79%; 20 cases of endometrial cancer positive rate of 80% in the corresponding normal tissues was 16.67% positive. 99mTc-LHRH mark was 97.9–100.0%, the radiochemical purity of 93.9–96.4%, marking the reaction gel content of <5%. Great product receptor marker analysis showed 99mTc-LHRH with saturable receptor binding characteristics and inhibition, and high affinity, RT = 23.2174 pmol, KD = 0.4348 nmol; intravenous injection of 131I-LHRH within 72 h after the mice rapidly cleared the blood radioactivity, the major radioactive accumulation in the liver and kidneys and by the liver, renal clearance, and other tissues and organs of the radioactivity gradually decreased with time. In conclusion, i) the liver, lung, breast, prostate, endometrial cancer exist in both LHRHR; ii) 99mTc-LHRH preparation is simple, rapid, radiochemical purity product obtained higher marks, better stability, no further purification; and iii) LHRH ...

show abstract

Section: Discussionmentioning

confidence: 99%

99mTc-LHRH in tumor receptor imaging

Hao

Sun

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…This result was not in accordance with the past experimental study. The experimental study of Suzuki et al demonstrated that the increase of 99 Tc m -HL91 uptake in tumors post irradiation predicted a poor response to radiation therapy, and that a decrease or no change suggested that radiation therapy would be effective [10] . The mechanisms of the T/N rising during radiotherapy may be: (1) Radiotherapy would consume oxygen in tumor tissue, and the oxygen pressure in tumor tissue would decrease to the lowest spot as soon as the radiotherapy was ended [11,12] .…”

Section: Discussionmentioning

confidence: 99%

A clinical study for evaluating early radiotherapy effect in patients with brain tumor using 99Tcm-HL91 spect

Zhao

Zhang

et al. 2006

Chin. J. Cancer Res.

View full text Add to dashboard Cite

Objective:The purpose of this study was to evaluate the early radiotherapy effect using 99 Tc m -HL91 SPECT in patients with brain tumors. Methods: Twenty-one patients with brain tumors who were treated by radiotherapy were studied. KPS grade, tumor size on 99 Tc m -HL91 SPECT , tumor size on MRI, and ratio of T/N (tumor counts/sec over normal brain tissue counts/sec) were investigated before ,during and after radiotherapy. Results: The average tumor size on 99 Tc m -HL91 SPECT and MRI was 11.34±5.88 cm 2 , 9.46±5.66 cm 2 , respectively before radiotherapy. The tumor size on 99 Tc m -HL91 SPECT was not in accordance with to that on MRI (P<0.05). KPS grade, tumor size on 99 Tc m -HL91 SPECT and ratio of T/N had significance differences before, during and after radiotherapy (P<0.05), but the tumor size on MRI imaging had no significance differences before, during and after radiotherapy (P>0.05). The rate of symptom improvement was 80% during radiotherapy and 100% after radiotherapy. The rates of imaging remission based on the brain tumor size on 99 Tc m -HL91 SPECT, MRI and T/N were 75%, 15%, and 80%, respectively during radiotherapy. The agreement rates between imaging remission diagnosed by those three methods and symptom improvement were 70%, 40%, and 60% respectively during radiotherapy. The rates of imaging remission based on the brain tumor sizes on 99 Tc m -HL91 SPECT, MRI and T/N were 100%, 25%, and 95% respectively after radiotherapy. The agreement rates between imaging remission diagnosed by those three methods and symptoms improvement were 100%, 20%, and 95% respectively after radiotherapy. Conclusion: The tumor size on 99 Tc m -HL91 SPECT is a valuable tool for evaluating early radiotherapy effect of brain tumor in process of radiotherapy. T/N is not a feasible method in evaluating radiotherapy effect of brain tumor because it may show elevation unrelated to the curative effect during radiotherapy.

show abstract

“…99m Tc-HL91 has also been used in clinical studies as a potential tracer to detect hypoxic myocardium. Information on the uptake of this marker, correlated with blood parameters, permits a measurement of the severity of hypoxia [102][103][104].…”

Section: N-chelating Ligandsmentioning

confidence: 99%

An insight into tumoral hypoxia: the radiomarkers and clinical applications

et al. 2009

View full text Add to dashboard Cite

Tumoral hypoxia is related to severe structural abnormalities of tumor microvessels, leading to deteriorated O 2 diffusion. This decreased O 2 concentration in cancer cells compromises cellular functions, besides being responsible for resistance to radiation therapy. Consequently, it is very important to know the hypoxic status of a tumor. In this review, the different methodologies available for evaluating cellular hypoxia in vivo are discussed, particularly those in which the hypoxia information is obtained through imaging. Among these the nuclear medicine approach uses ligands to complex with radionuclides. The resulting radioactive complexes which may be single photon or positron emitters, are very useful as imaging probes. The nature of ligands and their corresponding complexes, with application or potential application as hypoxia detectors, will be described. A summary of the most significant results so far obtained in clinical or preclinical applications will also be discussed.

show abstract

Monitoring of response to radiation therapy for human tumor xenografts using99mTc-HL91 (4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime)

Cited by 10 publications

References 12 publications

99mTc-LHRH in tumor receptor imaging

99mTc-LHRH in tumor receptor imaging

A clinical study for evaluating early radiotherapy effect in patients with brain tumor using 99Tcm-HL91 spect

An insight into tumoral hypoxia: the radiomarkers and clinical applications

Contact Info

Product

Resources

About